Crinetics Pharmaceuticals (CRNX) Fundamentals 2026 — Revenue Analysis | SniperIQ
Crinetics Pharmaceuticals (CRNX) is a US-listed Healthcare company in Biotechnology with a market capitalization of $8.9B, trading at $83.89 on the NASDAQ. This SniperIQ fundamentals page covers Crinetics Pharmaceuticals's valuation, profitability (net margin -2747.2%), revenue ($8M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Crinetics Pharmaceuticals's market cap?
Crinetics Pharmaceuticals (CRNX) has a market capitalization of approximately $8.9B, trading at $83.89 on the NASDAQ. Market cap moves with the live share price.
What is Crinetics Pharmaceuticals's P/E ratio?
Crinetics Pharmaceuticals's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 6.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Crinetics Pharmaceuticals?
Crinetics Pharmaceuticals runs a net profit margin of -2747.2%, a gross margin of 98.9%, and an operating margin of -3020.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Crinetics Pharmaceuticals generate?
Crinetics Pharmaceuticals reported revenue of $8M for fiscal year 2025, with net income of -$465M and earnings per share (EPS) of -4.95. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Crinetics Pharmaceuticals pay a dividend?
Crinetics Pharmaceuticals does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Crinetics Pharmaceuticals financially healthy?
Crinetics Pharmaceuticals carries a debt-to-equity ratio of 0.04x and a current ratio of 18.60x, with a market beta of 0.23. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Crinetics Pharmaceuticals a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Crinetics Pharmaceuticals (CRNX) the key facts are: market cap $8.9B, revenue $8M, 52-week range 25.83-84. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Crinetics Pharmaceuticals's full fundamentals live
Get Crinetics Pharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.